MyoKardia to create HCM community in collaboration with 23andMe
MyoKardia announced that it has entered into a collaboration with 23andMe to advance research for patients with hypertrophic cardiomyopathy, or HCM, a progressive and frequently debilitating disease characterized by excessive contractility of the heart. MyoKardia is committed to raising awareness and supporting patients and families suffering from this devastating disease, a commitment shared by 23andMe. The goal of this initiative is to deepen disease understanding and build resources intended to benefit patients and their caregivers. Together, the companies will collaborate to improve the baseline understanding of unmet need in the HCM disease area, including patient burden, quality of life, standard of care and variability of symptoms, improve knowledge of disease progression and natural history, and empower patient advocacy. The companies will create a patient community where 23andMe customers can access regularly-updated disease information and HCM research opportunities. More than 6,000 HCM patients are currently 23andMe customers. In addition, a custom survey will be deployed to collect baseline and follow-up longitudinal data from participants with HCM who have opted-in to participate in further research. MyoKardia and 23andMe intend to study this set of de-identified, population-scale phenotypic and genotypic data in order to gain unique insights that may support the broader HCM ecosystem. Summary results will be made available to patients through the 23andMe platform.